What's at stake: BioOra is making steady progress on building manufacturing capability to deliver Car T-cell therapies for a type of lymphoma.
The background: The Malaghan Institute of Medical Research set up BioOra with venture capital firm Bridgewest Ventures in 2021 after the success of a Phase 1 trial on a Car T-cell therapy, the first such home-grown treatment in New Zealand. It's trying to forge a regulatory and funding pathway for Car T-cell treatments in New Zealand, as patients currently have to travel overseas.
The players: Malaghan Institute, BioOra, Bridgewest Ventures, Medsafe, Pharmac, Health New Zealand.
Biotech therapeutics company BioOra tripled its valuation to $60m when raising $15m in a Series A round that closed last month.
The company is developing New Zealand manufacturing to deliver novel chimeric antigen receptor (Car T-cell) therapies that reprogramme a patient’s own immune cells to
Sign up to get the latest stories and insights delivered to your inbox – free, every day.
Key points
What's at stake: BioOra is making steady progress on building manufacturing capability to deliver Car T-cell therapies for a type of lymphoma.
The background: The Malaghan Institute of Medical Research set up BioOra with venture capital firm Bridgewest Ventures in 2021 after the success of a Phase 1 trial on a Car T-cell therapy, the first such home-grown treatment in New Zealand. It's trying to forge a regulatory and funding pathway for Car T-cell treatments in New Zealand, as patients currently have to travel overseas.
The players: Malaghan Institute, BioOra, Bridgewest Ventures, Medsafe, Pharmac, Health New Zealand.
